BC Cancer Protocol Summary for Adjuvant Treatment of Post-Menopausal Women Using 3-Monthly Zoledronic Acid

Protocol Code: BRAJZOL2
Tumour Group: Breast
Contact Physician: Dr. Stephen Chia

ELIGIBILITY:
- Initial stage II or III only (pT2-4 pN0-3; pT0-4pN1-3), or
- Post neo-adjuvant chemotherapy stage ypT2-4 ypN0-3; ypT0-4 ypN1-3
- Biomarkers: ER any PR any
- Adequate renal function (CrCl ≥ 30 mL/min)
- Bisphosphonate therapy must begin within 1 year of diagnosis

TESTS:
- Completion of necessary dental assessment and dental work is recommended prior to starting zoledronic acid
- Baseline and prior to each treatment: serum creatinine
- If clinically indicated: serum calcium* and albumin (or ionized calcium)
  *corrected calcium (mmol/L) = total calcium (mmol/L) + (0.02 x [40 – albumin in g/L])

PREMEDICATIONS:
- None

TREATMENT:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BCCA Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>zoledronic acid</td>
<td>4 mg</td>
<td>IV in 100 mL NS over 15 minutes</td>
</tr>
</tbody>
</table>

Repeat once every 3 months (12 weeks) for 2 years

DOSE MODIFICATIONS:

1. Renal dysfunction: Zoledronic acid

<table>
<thead>
<tr>
<th>Creatinine clearance (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;60</td>
<td>4 mg</td>
</tr>
<tr>
<td>50-60</td>
<td>3.5 mg</td>
</tr>
<tr>
<td>40-49</td>
<td>3.3 mg</td>
</tr>
<tr>
<td>30-39</td>
<td>3 mg</td>
</tr>
<tr>
<td>&lt; 30</td>
<td>not recommended</td>
</tr>
</tbody>
</table>

- There is limited experience with zoledronic acid in patients with serum creatinine greater than 440 micromol/L; caution is required.
PRECAUTIONS:
1. Zoledronic acid should NEVER be given as a bolus since severe local reactions and thrombophlebitis may result from high concentrations.
2. **Symptomatic hypocalcemia** (e.g., muscle spasms, irritability) may occur and may require calcium supplement. Avoid concomitant use of other calcium lowering agents such as corticosteroids and loop diuretics.
3. After the use of bisphosphonates, there is a persistent risk of jaw osteonecrosis. Patients in whom bisphosphonates are planned should have prophylactic assessment and management by a dentist and all later dental work should be undertaken cautiously by dental specialists experienced in the recognition and management of jaw osteonecrosis.

Call Dr. Stephen Chia or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

References: